medigraphic.com

2013, Number 1

<< Back Next >>

Rev Mex Anest 2013; 36 (1)

Fospropofol. Current concepts

Carrillo-Esper R, Nava-López JA, Rocha-Alvarado SA, Vargas-González FI

Language: Spanish
References: 13
Page: 56-59
PDF size: 86.29 Kb.


ABSTRACT

Propofol is the anesthetic mainly used for monitored anesthetic care sedation and during intravenous anesthesia. Propofol, a lipid macroemulsion, have several disadvantages including pain on injection, narrow therapeutic window with potential to cause deep sedation, high lipid intake during long-term sedation, and risk of infection. Fospropofol is a water soluble prodrug of propofol. Due to its water solubility, fospropofol eliminates the known lipid-emulsion associated disadvantages of propofol and provides a more predictable peak onset of activity and more gradual recovery. The pharmacokinetic and pharmacodynamics profiles of fospropofol make it an attractive agent for sedation. This review discusses the pharmacology and clinical uses of fospropofol, as well as, the benefits and disadvantages.


REFERENCES

  1. Bryson EO, Frost EA. Propofol abuse. Int Anesthesiol Clin 2011;49:173-180.

  2. Pergolizzi JV, Gan TJ, Plavin S, Labhsetwar S, Taylor R. Perspectives on the role of fospropofol in monitored anesthesia care setting. Anesthesiol Res Pract [Internet] 2011 [Cited: May 5, 2012]. Available in: http://www.hindawi.com/journals/arp/2011/458920/

  3. Harris EA, Lubarsky DA, Candiotti KA. Monitored anesthesia care (MAC) sedation: clinical utility of fospropofol. Therapeutics and Clinical Risk Management 2009;5:949-959.

  4. Moore GD, Walker AM, MacLaren R. Fospropofol: a new sedative-hypnotic agent for monitored anesthesia care. Annals of Pharmacotherapy 2009;43:1802-1808.

  5. Shah A, Mistry B, Gibiansky E, Gibiansky L. Fospropofol assay issues and impact on pharmacokinetic and pharmacodynamic evaluation: retraction. Anesthesiology 2010;112:1058.

  6. Krasowski MD. GPI-15715 Guilford. Current Opinion in Investigational Drugs 2005;6:90-98.

  7. Gan TJ. Pharmacokinetic and pharmacodynamic characteristics of medications used for moderate sedation. Clinical Pharmacokinetics 2006;45:855-869.

  8. Schywalsky M, Ihmsen H, Tzabazis A, Fechener J, Burak E, Vornov J, Schwilden H. Pharmacokinetics and pharmacodynamics of the new propofol prodrug GPI 15715 in rats. Eur J Anaesthesiol 2003;20:182-190.

  9. Cohen LB. Clinical trial: a dose-response study of fospropofol disodium for moderate sedation during colonoscopy. Alimentary Pharmacology and Therapeutics 2008;27:597-608.

  10. Cohen LB, Cattau E, Goetsch A. A randomized, double-blind, phase 3 study of fospropofol disodium for sedation during colonoscopy. Journal of Clinical Gastroenterology 2010;44:345-353.

  11. Rex D, Cohen L, Klein J, Wang C. Fospropofol disodium is effective and safe for sedation in patients undergoing colonoscopy: results of a phase 3, randomized, double-blind trial. In Digestive Disease Week; Washington, DC, USA; 2007.

  12. Gan TJ, Berry BD, Ekman EF, Muckerman RC, Shore N, Hardi R. Safety evaluation of fospropofol for sedation during minor surgical procedures. Journal of Clinical Anesthesia 2010;22:260-267.

  13. Silvestri GA, Vincent B, Wahidi MM, Robinette E, Hansbrought JR, Downie GH. A phase 3, randomized, double blind study to asses the efficacy and safety of fospropofol disodium injection for moderate sedation in patients undergoing flexible bronchoscopy. Chest 2009;135;41-47.




2020     |     www.medigraphic.com